Article

Debu Tripathy Discusses a Clinical Trial of Ibrance in Breast Cancer

Author(s):

Debu Tripathy

Debu Tripathy, editor-in-chief of CURE and chair of the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses adding the targeted drug Ibrance to the hormonal drug Faslodex.

Debu Tripathy, editor-in-chief of CURE and chair of the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses adding the targeted drug Ibrance to the hormonal drug Faslodex.

This trial, of women with previously treated hormone receptor-positive, HER2-negative breast cancer, was presented during the 2015 annual meeting of the American Society of Clinical Oncology, a gathering of nearly 30,000 oncology professionals taking place in Chicago.

Read more about the trial here.

Related Videos
Image of a man in a suit.
Image of woman with brown hair.
Image of a man with short hair, wearing a buttoned-up shirt.
Image of a man with short black hair.
Image of a woman with wavy blonde hair wearing glasses.
Image of a woman with tied back hair, wearing pearl earrings.
Image of a woman with layered hair, wearing a bright blue cardigan.
Image of a man with short black hair.
Image of man with gray hair.
Image of woman with black hair.
Related Content
Image of woman holding ribbon.
October 28th 2024

Radiation May Cause Secondary Cancer in Some Breast Cancers

Ashley Chan
Receiving radiation therapy for breast cancers harboring TP53 germline variants may cause secondary cancers, but risk estimates are unconfirmed.
FDA, Cancer Vaccine Updates and a Misguiding of Breast Cancer Treatment
February 5th 2024

FDA, Cancer Vaccine Updates and a Misguiding of Breast Cancer Treatment

Alex Biese Brielle Benyon
One cancer vaccine may still be years away from being available, a breast cancer test may be misguiding treatments for Black women and the review of two oncology regimens are being expedited by the FDA.
illustration of metastatic breast cancer
October 24th 2024

Trodelvy Is Effective in Real-World Patients With Breast Cancer Subset

Spencer Feldman
Trodelvy shows effectiveness in real-world breast cancer treatment, even after receiving Enhertu therapy.
Cancer Horizons podcast logo
December 12th 2023

Conference Highlights from SABCS

Alex Biese Brielle Benyon
CURE® recently covered the San Antonio Breast Cancer Symposium. In case you missed it, here is some news that came out of the conference that patients should know about.
An open hand with a heart above it in front of a colorful background.
October 20th 2024

Selfless Acts of Service in Cancer Care

Marie Davis, RN-BSN Natosha Williams
A colleague and a patient with cancer each submitted nominating essays about an oncology nurse who made an impact in their lives.
Illustration of a woman with shoulder-length gray hair, wearing round glasses.
October 18th 2024

Pinktober: A Whole Family Commemorates the Breast Cancer Experience

Sue McCarthy
As someone who disliked pink for years, it has grown on me over time, especially after having breast cancer.